Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SER-214 (Serina Therapeutics, Inc., 1c3114)
- Development stage
- Unknown
- Lead developer
- Serina Therapeutics
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Subcutaneous
01
Overview
SER-214 (SRx-503) is a polymer-drug conjugate consisting of the dopamine agonist ropinirole covalently attached to a polyoxazoline (POZ) polymer backbone. Developed by Serina Therapeutics, this long-acting injectable is designed to provide continuous dopaminergic stimulation for patients with Parkinson's disease. By utilizing the proprietary POZ platform, SER-214 achieves a sustained-release profile that maintains stable plasma concentrations of ropinirole over a one-week period following a single subcutaneous injection. This approach aims to mitigate the motor fluctuations and dyskinesia typically associated with the pulsatile receptor stimulation of short-acting oral levodopa or dopamine agonists.
- Other names
- ropinirole polyoxazolinepolyoxazoline-ropinirole
02
Targets
DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)DRD4 (Dopamine D4 Receptor)DRD5 (Dopamine D5 Receptor)
Beyond the preview
Go deeper on SER-214 (Serina Therapeutics, Inc., 1c3114).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SER-214 (Serina Therapeutics, Inc., 1c3114).